Cipla-Serum add new rung to relationship
This article was originally published in Scrip
This could be read as growing pre-nuptial synergy between Cipla and the Serum Institute of India. Or maybe the duo's next step in their "relationship" is purely an extension of a previous alliance and one which will see Cipla step up its indirect interest in vaccines play to the Indian market.
You may also be interested in...
Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.
Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.
Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.